Skip to main content

Table 2 Clinicopathologic characteristics according to BRAF mutation status

From: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients

  Patients with BRAF status p-value
Negative Positive Total
(N = 1052) (N = 44) (N = 1096)
Sex     0.149
 Male 652 (62.0%) 22 (50.0%) 674 (61.5%)  
 Female 400 (38.0%) 22 (50.0%) 422 (38.5%)  
Age     0.375
  < 50 year 131 (12.5%) 8 (18.2%) 139 (12.7%)  
  ≥ 50 year 921 (87.5%) 36 (81.8%) 957 (87.3%)  
Location     0
 Rt colon 252 (24.0%) 25 (56.8%) 277 (25.3%)  
 Lt colon 455 (43.3%) 14 (31.8%) 469 (42.8%)  
 Rectum 324 (30.8%) 4 (9.1%) 328 (29.9%)  
 Multiple 21 (2.0%) 1 (2.3%) 22 (2.0%)  
Stage     0.226
 Tis 23 (2.2%) 0 (0.0%) 23 (2.1%)  
 StageI 205 (19.6%) 5 (11.4%) 210 (19.2%)  
 StageII 323 (30.9%) 12 (27.3%) 335 (30.7%)  
 StageIII 496 (47.4%) 27 (61.4%) 523 (47.9%)  
T stage     0.006
 T1 93 (9.1%) 3 (6.8%) 96 (9.0%)  
 T2 173 (16.9%) 4 (9.1%) 177 (16.6%)  
 T3 637 (62.1%) 24 (54.5%) 661 (61.8%)  
 T4 122 (11.9%) 13 (29.5%) 135 (12.6%)  
N stage     0.015
 N0 553 (52.7%) 17 (38.6%) 570 (52.1%)  
 N1 282 (26.9%) 10 (22.7%) 292 (26.7%)  
 N2 215 (20.5%) 17 (38.6%) 232 (21.2%)  
M stage     
 M0 3 (75.0%) 0 (0.0%) 3 (75.0%)  
 M1 1 (25.0%) 0 (0.0%) 1 (25.0%)  
Lymphatic invasion     0.007
 Absent 588 (56.0%) 15 (34.1%) 603 (55.1%)  
 Present 462 (44.0%) 29 (65.9%) 491 (44.9%)  
Venous invasion     0.109
 Absent 873 (83.2%) 32 (72.7%) 905 (82.8%)  
 Present 176 (16.8%) 12 (27.3%) 188 (17.2%)  
Perineural invasion     0.451
 Absent 804 (76.6%) 31 (70.5%) 835 (76.3%)  
 Present 246 (23.4%) 13 (29.5%) 259 (23.7%)  
Differentiation     0.081
 Well 96 (9.5%) 2 (5.0%) 98 (9.4%)  
 Moderate 875 (86.9%) 34 (85.0%) 909 (86.8%)  
 Poor 36 (3.6%) 4 (10.0%) 40 (3.8%)  
Histology     0.302
 Non-mucinous adenocarcinoma 986 (93.7%) 39 (88.6%) 1025 (93.5%)  
 Mucinous adenocarcinoma 66 (6.3%) 5 (11.4%) 71 (6.5%)  
Recur     0.113
 Recur 894 (85.0%) 33 (75.0%) 927 (84.6%)  
 Non-recur 158 (15.0%) 11 (25.0%) 169 (15.4%)  
Expire     0
 Expire 956 (90.9%) 32 (72.7%) 988 (90.1%)  
 Non-Expire 96 (9.1%) 12 (27.3%) 108 (9.9%)  
Neoadjuvant Tx     0.589
 No 929 (88.3%) 41 (93.2%) 970 (88.5%)  
 CTx 40 (3.8%) 2 (4.5%) 42 (3.8%)  
 RT 2 (0.2%) 0 (0.0%) 2 (0.2%)  
 CCRT 81 (7.7%) 1 (2.3%) 82 (7.5%)